FDA Approves Rx/Dx Combination for Acute Myeloid Leukemia

NEW YORK (GenomeWeb) – The US Food and Drug Administration today approved Novartis’ acute myeloid leukemia drug Rydapt (midostaurin) in combination with chemotherapy alongside Invivoscribe Technologies’ LeukoStrat CDx FLT3 Mutation Assay to identify patients who can receive the drug.

Get the full story This story is free
for registered users

Registering provides access to this and other free content.

Already have an account?
.

Be the first to comment

Leave a Reply

Your email address will not be published.


*